The CeCORD-J study on collagenase injection versus aponeurectomy for Dupuytren's contracture compared by hand function and cost effectiveness

Sci Rep. 2022 May 31;12(1):9094. doi: 10.1038/s41598-022-12966-z.

Abstract

This study compared hand function and the cost-effectiveness of treatment between collagenase Clostridium histolyticum (CCH) injection and limited fasciectomy for patients with Dupuytren's contracture (DC). The CeCORD-J study is a prospective, multicenter, non-randomized controlled, observational study of two parallel groups. Participants were DC patients with multiple affected fingers, including flexion contracture of the proximal interphalangeal (PIP) joint. The primary outcome was the Hand10 score, as a patient-reported outcome measure (PROM). We set secondary outcomes of EQ-5D-5L (QOL) score, degree of extension deficit, and direct cost. Propensity score adjustment was used to balance differences in patient characteristics between groups. Participants comprised 52 patients in the Collagenase group and 26 patients in the Surgery group. There were no significant differences in the Hand10 and QOL scores between the two groups at 26 weeks. Mean direct cost was 248,000 yen higher in the Surgery group than in the Collagenase group. Extension deficit angle of the PIP joint was significantly larger in the Collagenase group at 26 weeks. Although the Collagenase group showed dominance in cost-effectiveness, there was no significant difference between the two groups in hand function at 26 weeks.

Publication types

  • Controlled Clinical Trial
  • Multicenter Study
  • Observational Study

MeSH terms

  • Collagenases
  • Cost-Benefit Analysis
  • Dupuytren Contracture* / drug therapy
  • Dupuytren Contracture* / surgery
  • Humans
  • Microbial Collagenase / therapeutic use
  • Prospective Studies
  • Quality of Life
  • Treatment Outcome

Substances

  • Collagenases
  • Microbial Collagenase